Modeling Effect of a γ-Secretase Inhibitor on Amyloid-β Dynamics Reveals Significant Role of an Amyloid Clearance Mechanism
- 273 Downloads
Aggregation of the small peptide amyloid beta (Aβ) into oligomers and fibrils in the brain is believed to be a precursor to Alzheimer’s disease. Aβ is produced via multiple proteolytic cleavages of amyloid precursor protein (APP), mediated by the enzymes β- and γ-secretase. In this study, we examine the temporal dynamics of soluble (unaggregated) Aβ in the plasma and cerebral-spinal fluid (CSF) of rhesus monkeys treated with different oral doses of a γ-secretase inhibitor. A dose-dependent reduction of Aβ concentration was observed within hours of drug ingestion, for all doses tested. Aβ concentration in the CSF returned to its predrug level over the monitoring period. In contrast, Aβ concentration in the plasma exhibited an unexpected overshoot to as high as 200% of the predrug concentration, and this overshoot persisted as late as 72 hours post-drug ingestion. To account for these observations, we proposed and analyzed a minimal physiological model for Aβ dynamics that could fit the data. Our analysis suggests that the overshoot arises from the attenuation of an Aβ clearance mechanism, possibly due to the inhibitor. Our model predicts that the efficacy of Aβ clearance recovers to its basal (pretreatment) value with a characteristic time of >48 hours, matching the time-scale of the overshoot. These results point to the need for a more detailed investigation of soluble Aβ clearance mechanisms and their interaction with Aβ-reducing drugs.
Keywordsγ-secretase inhibitor Amyloid-β clearance
Unable to display preview. Download preview PDF.
- Deane, R., Yan, S. Du, Submamaryan, R.K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., Zhu, H., Ghiso, J., Frangione, B., Stern, A., Schmidt, A.M., Armstrong, D.L., Arnold, B., Liliensiek, B., Nawroth, P., Hofman, F., Kindy, M., Stern, D., Zlokovic, B., 2003. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 9, 907–913. CrossRefGoogle Scholar
- Efron, B., Tibshirani, R.J., 1994. An Introduction to the Bootstrap. Chapman and Hall, London. Google Scholar
- Evans, D.A., Funkenstein, H.H., Albert, M.S., Scherr, P.A., Cook, N.R., Chown, M.J., Hebert, L.E., Hennekens, C.H., Taylor, J.O., 1989. Prevalence of Alzheimer’s disease in a community population of older persons. Higher than previously reported. J. Am. Med. Assoc. 262, 2551–2556. CrossRefGoogle Scholar
- Gilberto, D.B., Zeoli, A.H., Szczerba, P.J., Gehret, J.R., Holahan, M.A., Sitko, G.R., Johnson, C.A., Cook, J.J., Motzel, S.L., 2003. An alternative method of chronic cerebrospinal fluid collection via the cisterna magna in conscious rhesus monkeys. Contemp. Top. Lab. Anim. Sci. 42, 53–59. Google Scholar
- Kandimalla, K.K., Curran, G.L., Holasek, S.S., Gilles, E.J., Wengenack, T.M., Poduslo, J.F., 2005. Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer’s disease transgenic mice (APP, PS1) and its implications for amyloid plaque formation. J. Pharmacol. Exp. Ther. 313, 1370–1378. CrossRefGoogle Scholar
- Nachbar, R.B., Pak, I., Spann, A., 2006. Kinetic models in biology and chemistry. Wolfram Technology Conference. URL http://library.wolfram.com/infocenter/Conferences/6463/.
- Rosen, L.B., Stone, J.A., Plump, A., Yuan, J., Harrison, T., Flynn, M., Dallob, A., Matthews, C., Stevenson, D., Schmidt, D., et al., 2006. The gamma-secretase inhibitor mk-0752 acutely and significantly reduces csf ab40 concentrations in humans. In: 10th International Conference on Alzheimer’s Disease and Related Disorders, Madrid. Abstract 04-03-02. Google Scholar
- Shibata, M., Yamada, S., Kumar, S.R., Calero, M., Bading, J., Frangione, B., Holtzman, D.M., Miller, C.A., Strickland, D.K., Ghiso, J., Zlokovic, B.V., 2000. Clearance of Alzheimer’s amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106, 1489–1499. CrossRefGoogle Scholar
- Siemers, E.R., Quinn, J.F., Kaye, J., Farlow, M.R., Porsteinsson, A., Tariot, P., Zoulnouni, P., Galvin, J.E., Holtzman, D.M., Knopman, D.S., Satterwhite, J., Gonzales, C., Dean, R.A., May, P.C., 2006. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 66, 602–604. CrossRefGoogle Scholar
- Tanzi, R.E., Moir, R.D., Wagner, S.L., 2004. Clearance of Alzheimer’s Abeta peptide: the many roads to perdition. Neuron 43, 605–608. Google Scholar
- Tian, G., Sobotka-Briner, C.D., Zysk, J., Liu, X., Birr, C., Sylvester, M.A., Edwards, P.D., Scott, C.D., Greenberg, B.D., 2002. Linear non-competitive inhibition of solubilized human gamma-secretase by pepstatin A methylester, L685458, sulfonamides, and benzodiazepines. J. Biol. Chem. 277, 31499–31505. CrossRefGoogle Scholar